Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine.
Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Our value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest currently employs more than 2,300 people worldwide.
The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe.
Biotest at a glance
Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. Our products are primarily used in the therapeutic areas of clinical immunology, haematology and intensive care medicine.
Global locations
Plasmapheresis centres
Distributors
Sustainability
Biotest is committed to its responsibility to manufacture and market vital medicines from human blood plasma with the HIGHEST SAFETY, QUALITY and EFFICIENCY in a CLIMATE-FRIENDLY WAY, while providing sustainable benefits to society, patients, employees and shareholders on our path to carbon neutrality by 2035.
GoFuture
Following our vision "Go Future", the management team committed to the goal of complete climate neutrality by 2035.
Sustainability in BNL
The commercial production of our plant “Biotest Next Level” is an important step on our way to a more sustainable manufacturing. This plant will make it possible for us to produce immunoglobulins and other plasma products more sustainably than before – at a consistently high quality level!
Sustainability report according to German sustainability code (DNK)
In our current Sustainability Report we give insights into our advanced sustainability strategy and transparently document the company’s sustainability-related achievements in detail.
Suppliers Code of Conduct
Commitment to Sustainibility
Biotest is committed to responsible corporate governance in accordance with internationally recognized standards, in particular the Universal Declaration of Human Rights of the United Nations (UN) as of below voluntary commitment.
Policy statement
The Supply Chain Due Diligence Act (LkSG) regulates corporate responsibility for compliance with human rights in global supply chains. This includes, for example, protection against child labor, the right to fair wages and protection of the environment.
Corporate social responsibility
Corporate social responsibility means not only a forward-looking approach to our business areas, but also cultural and social engagement.
Anti-counterfeiting
The counterfeiting of medicines is a criminal and highly irresponsible act. Every year, tons of counterfeit medicines are seized, including painkillers and medicines to treat cancer or HIV infections. To counteract this, the authorities and the pharmaceutical industry is increasingly working on improved counterfeit protection for pharmaceuticals.
Ambition and values
We set the following ambitions for ourselves and our partners.
Diversity
Biotest meets nationally and internationally recognised employee rights standards, and promotes the participation of employees in the company's sustainability management.
Areas of activity
As a fully integrated supplier, Biotest covers the entire value chain for drug manufacturing – from pre-clinical and clinical development of new products and from collecting plasma as the core raw material for plasma protein products, to manufacturing, marketing and global sales.
Products
Currently Biotest markets 14 different products in three therapeutic areas in clinical immunology, haematology and intensive care medicine, further are in the pipeline. These are special products that are prescribed for various indications.
Processes
The plasma protein manufacturing value chain comprises the following key steps.
Mission, vision and strategy
Biotest’s mission, vision and strategy reflects the company’s goals.
Mission
At Biotest we work to provide effective help to patients with serious blood or immune diseases and to enable them to lead the most independent and normal lives possible.
Vision
Biotest will continue to develop as a global provider of biological pharmaceuticals in the therapeutic areas of haematology, clinical immunology and intensive care medicine. Our goal is to offer drugs that set benchmarks for efficacy, tolerability and convenience.
Strategy
The Biotest Group has grown its core business continuously over recent years. We want to continue along this path at a faster pace.
Biotest Next Level
Biotest will more than double the production capacity of the Biotest Group with the "Biotest Next Level" investment programme.
Compliance
We have defined our view of a correct and proper relationship with business partners, shareholders, employees, colleagues and public authority representatives in a compliance declaration.
Biotest Code of Ethics and Business Conduct
Blowing the whistle
Transparency/Disclosure Data
Scientific engagement
Promotion of science and research.
Cooperation with patient organisations and physicians.
Committment to Sustainibility
Biotest is committed to responsible corporate governance in accordance with internationally recognized standards, in particular the Universal Declaration of Human Rights of the United Nations (UN) as of below voluntary commitment.
